Table 1.
Relative risk of major coronary events by simvastatin in patients defined by baseline quarters of total, low density lipoprotein and high density lipoprotein cholesterol and triglyceride concentrations, body mass index, and cholestanol proportion
| Variable | First quarter
|
Second quarter
|
Third quarter
|
Fourth quarter
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | Relative risk (95% CI) | Value | Relative risk (95% CI) | Value | Relative risk (95% CI) | Value | Relative risk (95% CI) | ||||
| Cholesterol (mmol/l) | <6.0 | 0.795 (0.538 to 1.17) | 6.0-6.6 | 0.652 (0.430 to 0.989) | 6.7-7.1 | 0.953 (0.637 to 1.44) | >7.1 | 0.763 (0.482 to 1.21) | |||
| Low density lipoprotein cholesterol (mmol/l) | <4.2 | 0.683 (0.445 to 1.05) | 4.2-4.6 | 0.823 (0.528 to 1.28) | 4.7-5.1 | 0.704 (0.478 to 1.04) | >5.1 | 0.926 (0.604 to 1.42) | |||
| High density lipoprotein cholesterol (mmol/l) | <1.0 | 0.856 (0.609 to 1.20) | 1.0-1.2 | 0.639 (0.425 to 0.961) | 1.3-1.4 | 0.859 (0.550 to 1.34) | >1.4 | 0.738 (0.419 to 1.30) | |||
| Triglycerides (mmol/l) | <1.1 | 0.972 (0.674 to 1.40) | 1.1-1.4 | 0.742 (0.457 to 1.20) | 1.5-1.9 | 0.681 (0.457 to 1.01) | >1.9 | 0.702 (0.447 to 1.10) | |||
| Body mass index (kg/m2) | <24.2 | 0.880 (0.589 to 1.32) | 24.2-26.4 | 0.737 (0.485 to 1.12) | 26.5-28.4 | 0.750 (0.493 to 1.14) | >28.4 | 0.791 (0.523 to 1.20) | |||
| Cholestanol (102 mmol/mol cholesterol)* | <107 | 0.623 (0.395 to 0.982) | 107-126 | 0.657 (0.426 to 0.998) | 127-148 | 0.753 (0.502 to 1.130) | >148 | 1.166 (0.791 to 1.720) | |||
*
In the four quarters, No (%) of events was 22 (21), 24 (23), 31 (26), and 38 (35) in simvastatin group and 37 (33), 39 (35), 36 (35), and 32 (30) in placebo group, respectively.